The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 2, 2013, Pages 110-115

  Bai, Hao ^a   Han, Baohui ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

Author keywords

brain metastases; epidermal growth factor receptor; erlotinib; mutation; non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; DEATH; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876123594     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182438c91     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865-2872.
4. Bajard A, Westeel V, Dubiez A, et al. Multivariate analysis of factors predictive of brain metastases in localized non-small cell lung carcinoma. Lung Cancer. 2004;45:317-323.
5. Gaspar LE, Chansky K, Albain KS, et al. Time to treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by Southwest Oncology Group. J Clin Oncol. 2005;23:2955-2961.
6. Carolan H, Sun AY, Bezjak A, et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer. 2005;49:109-115.
7. Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242:882-888.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21:2237-2246.
9. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
10. Shepherd FA, Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353: 123-132.
11. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:227-231.
12. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Onco1. 2004;15:1042-1047.
13. Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004;6:123-128.
14. Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib (Iressa, ZD1839) on brain metastases in patients with advanced non-small lung cancer. Lung Cancer. 2004;46:255-261.
15. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology (RTOG) brain metastases trial. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
17. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 2004;22: 3238-3247.
18. Tiseo M, Gridelli C, Cascinu S, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer. 2009;64:199-206.
19. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007;13:1511-1515.
20. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5:950-955.
21. Lai CS, Boshoff C, Falzon M, et al. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax. 2006;61:91.
22. Popat S, Hughes S, Papadopoulos P, et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer. 2007;56:135-137.
23. Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J Clin Oncol. 2007;25: 5024-5026.
24. Von Pawel G, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case report. Onkologie. 2008;31:123-126.
25. Altavilla G, Arrigo C, Santarpia MC, et al. Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol. 2008;90:31-33.
26. Gounant V, Wislez M, Poulot V, et al. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer. 2007;58:425-428.
27. Benedetti G, Latini L, Galetta D, et al. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two case of non-small cell lung cancer treated with erlotinib. J Thorac Oncol. 2009;4:936-937.
28. Ruppert AM, Beau-Faller M, Neuville A, et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J. 2009;33:436-440.
29. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4:1415-1419.
30. Masago K, Togashi Y, Fukudo M, et al. Good clinical response to erlotinib in a non-small cell lung cancer patient harbouring multiple brain metastases and a double active somatic epidermal growth factor gene mutation. Case Rep Oncol. 2010;3:98-105.
31. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37:624-631.
32. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
33. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced nonsmall-cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol. 2006;24:369s.
34. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer. J Clin Oncol. 2005;23:2493-2501.
35. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Clin Cancer Res. 2005;16: 1081-1086.
36. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer. 2007;96:857-863.
37. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
38. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
39. Pao W, Miller VA, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
40. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
41. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory and advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.